Dose-Dependent Anti-Inflammatory and Neuroprotective Effects of an ανβ3 Integrin-Binding Peptide

Figure 3

Medium- to high-dose C16 therapy reduced CD4⁺ lymphocytes extravasation (a). C16 late treatment also inhibited CD4⁺ lymphocytes extravasation to a certain extent (b). Medium to high-dose C16 treatment also reduced CD45⁺ leukocytes infiltration (c). C16 late treatment also inhibited CD45⁺ leukocytes infiltration to a certain extent (d). Medium to high-dose C16 treatment reduced CD68⁺ macrophages extravasation (e). Late treated C16 treatment also inhibited CD68⁺ macrophages extravasation to a certain extent (f). ((a), (c), (e)) ^a𝑃<0.05 versus normal rats; ^b𝑃<0.05 versus vehicle control rats at week 2 postimmunization group; ^c𝑃<0.05 versus 0.5 mg/per day C16 treated EAE rats at week 2 after immunization. ^f𝑃<0.05 versus vehicle control rats at week 8 after immunization; ^g𝑃<0.05 versus 0.5 mg/per day C16 treated EAE rats at week 8 after immunization. ((b), (d), and (f)) ^a𝑃<0.05 versus normal rats; ^b𝑃<0.05 versus vehicle control rats at week 2 postimmunization group; ^c𝑃<0.05 versus C16 treated EAE rats at week 2 postimmunization group; ^d𝑃<0.05 versus vehicle control rats at week 8 after immunization.

(a)

(b)

(c)

(d)

(e)

(f)